PUSHOCTII: Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix

Sponsor
Preventive Oncology International, Inc. (Other)
Overall Status
Completed
CT.gov ID
NCT01766284
Collaborator
Imalux (Other)
100
1
1

Study Details

Study Description

Brief Summary

Optical Coherence Tomography (OCT) is a technology using harmless near infra-red light scatter to produce an image. Prior studies with OCT have demonstrated that OCT of the uterine cervix can differentiate between grades of pre-invasive and invasive cervical disease and cancer. This study will evaluate the ability of the NIRIS 1300e imaging (OCT) system to detect pre-invasive cervical disease and cervical cancer.

Condition or Disease Intervention/Treatment Phase
  • Device: NIRIS 1300e
N/A

Detailed Description

  1. Specific Aims
  1. Primary. To determine the sensitivity, specificity, positive and negative predictive values for Niris 1300e OCT enhanced gynecologic examination (VIA-OCT vs.colposcopy-biopsy) for the detection of lesions equal or greater than cervical intraepithelial neoplasia II (CIN II) and cancer in a "real time" clinical evaluation.

  2. Secondary. To examine the ease of use of Niris 1300e OCT in a real time clinical setting in order to assess its potential application during a "see and treat" or "single episode of care" clinic visit.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix (PUSHOCTII)
Study Start Date :
Nov 1, 2012
Actual Primary Completion Date :
Nov 1, 2012
Actual Study Completion Date :
Nov 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Niris 1300e OCT imaging

OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.

Device: NIRIS 1300e
Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.

Outcome Measures

Primary Outcome Measures

  1. To determine the accuracy of VIA plus Niris 1300e OCT enhanced gynecologic examination. [Study will be completed over a 4 day period with OCT and brightness determination as each patient is seen. During the next 4 months, we will conduct blinded reviews of the images to determine new sets of brightness numbers.]

Secondary Outcome Measures

  1. To compare OCT image (Niris 1300e) technology directly to colposcopy with biopsy for the detection of lesions equal or greater than cervical intraepithelial neoplasia II (CIN II) and cancer in a "real time" clinical evaluation. [Study will be completed over a 4 day period with OCT and brightness determination as each patient is seen. During the next 4 months we will conduct blinded reviews of the images to determine new sets of brightness numbers.]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Female subjects > 18 years of age

  2. Subject must voluntarily sign a Patient Informed Consent Form specific to the study.

  3. Subject must be physically and mentally willing to comply with all study requirements, especially conduct of a colposcopy exam.

  4. Participant must be attending the Center for Cervical Diagnosis.

Exclusion Criteria:
  1. Based on clinical history, physical exam and patient presentation, the subject is unable to provide adequate informed consent and/or comply with the study requirements.

  2. Subject is a prisoner.

  3. Subject is pregnant.

  4. Subject has had a hysterectomy

  5. Subject has received prior pelvic radiotherapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Shenzhen Hospital Shenzhen Guangdong China 518036

Sponsors and Collaborators

  • Preventive Oncology International, Inc.
  • Imalux

Investigators

  • Principal Investigator: Jerome L Belinson, MD, Preventive Oncology International
  • Principal Investigator: Rufiang Wu, MD, Peking University Shenzhen Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Preventive Oncology International, Inc.
ClinicalTrials.gov Identifier:
NCT01766284
Other Study ID Numbers:
  • PUSHOCTII
First Posted:
Jan 11, 2013
Last Update Posted:
Feb 15, 2013
Last Verified:
Feb 1, 2013

Study Results

No Results Posted as of Feb 15, 2013